BriaCell Therapeutics Corp Ordinary Shares - New BCT

Morningstar Rating
CA$4.40 −0.26 (5.58%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BCT is trading at a LOCK|G&&$ premium.
Price
CA$4.66
Fair Value
LOCK|B^#zn@
Uncertainty
LOCK|Ql h%gpy
1-Star Price
LOCK|.FB>@S%!
5-Star Price
LOCK|@F^bq&V
Economic Moat
LOCK|<z%@
Capital Allocation
—

News

Trading Information

Previous Close Price
CA$4.66
Day Range
CA$4.34–4.45
52-Week Range
CA$3.68–18.00
Bid/Ask
CA$4.18 / CA$5.50
Shares Outstanding
8.73M
Market Cap
CA$38.42M
Volume/Avg
1,305 / 6,974

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
31

Valuation

Metric
BCT
Price/Earnings (Normalized)
—
Price/Book Value
—
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
BCT

Financial Strength

Metric
BCT
Quick Ratio
2.66
Current Ratio
2.76
Interest Coverage
−1,212.56
Quick Ratio
BCT

Profitability

Metric
BCT
Return on Assets (Normalized)
−142.87%
Return on Equity (Normalized)
—
Return on Invested Capital (Normalized)
−179.62%
Return on Assets
BCT

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|pGZg#s%LOCK|G>^?$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|cq@^mQvLOCK|F!Wg>$95B
Moderna Inc
MRNA
LOCK|GCK$?PLOCK|%<$79B
argenx SE ADR
ARGX
LOCK|s#j%&QsLOCK|pW$59B
BeOne Medicines Ltd ADR
ONC
LOCK|<^ZR?!LOCK|^^$45B
Royalty Pharma PLC Class A
RPRX
LOCK|&f<!^m!LOCK|zj>x^$30B
Incyte Corp
INCY
LOCK|twbqV<LOCK|N?$23B
BioNTech SE ADR
BNTX
LOCK|d&<yGnLOCK|^!#$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|psQkWw$LOCK|pbr<@$19B
BridgeBio Pharma Inc
BBIO
LOCK|J>z?Y^PLOCK|Hk$15B

Sponsor Center